Lille , Cambridge , Zurich , April 25, 2024 - GENFIT , a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced.
Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical.
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Dr. Leen Kawas, Managing General Partner at Propel Bio Partners, highlights the myriad of ways in which a diverse management team can positively impact an entire workforce. In today’s increasingly global business landscape, workers with different nationalities and cultural profiles often come together to help achieve a company’s mission. Individuals…